Enoxaparin Sodium Market Size, Share, Growth and Industry Analysis, By Type (30 mg/0.3mL, 60 mg/0.6mL, 100 mg/1mL, 120 mg/0.8mL, 150 mg/1mL), By Application (Hospital, Clinic, Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

ENOXAPARIN SODIUM MARKET OVERVIEW

The global enoxaparin sodium market size is anticipated to be valued at USD 5.14 Billion in 2026, with a projected growth to USD 12.38 Billion by 2035 at a CAGR of 10.25% during the forecast from 2026 to 2035.

Enoxaparin sodium is a weight-thinning (blood-thinning) anticoagulant heparin. It is used to treat and prevent deep vein thrombosis and pulmonary embolism, and to treat and prevent blood clots during pregnancy and after certain types of surgery. Pulmonary embolism occurs when blood clots travel through the lungs and attach to pulmonary blood vessels. This drug is prescribed for a certain period after knee or hip replacement surgery, and also in some cases abdominal surgery and also in connection with a serious illness. In addition, enoxaparin sodium is used in patients with acute coronary syndrome (ACS) and heart attack. It is injected into a vein or just under the skin. Bleeding, fever and leg swelling are all common side effects. Bleeding can be dangerous, especially if the person has back pain.

The market is further fueled by an aging population that is more prone to cardiovascular disease and venous thromboembolism. In addition, advancements in medical technologies and growing awareness of the benefits of anticoagulant therapy are fueling the market expansion.

KEY FINDINGS

COVID-19 IMPACT

COVID-19 adversely affected the market growth due to reduction in product demand

The COVID-19 pandemic has been unprecedented and staggering, with the enoxaparin sodium market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

COVID-19 can affect the economy in three main ways: by directly affecting the production and demand for drugs, prebiotics, probiotics, medical devices, etc., by disrupting distribution channels, and by economic impact on companies and financial markets. Due to nationwide lockdowns, several countries like China, India, Saudi Arabia, UAE, Egypt and others are facing problems in transporting drugs from one place to another. However, the COVID-19 pandemic has had a positive impact on the global enoxaparin sodium market due to increased research and development activities for the development of enoxaparin sodium for the treatment of COVID-19. Prospective cohorts and randomized controlled clinical trials (RCT) are urgently needed to investigate the definitive effect of low molecular weight heparin to provide direct definitive evidence.

LATEST TRENDS

Deep vein thrombosis segment is expected to grow significantly during the forecast period

Deep vein thrombosis, also known as venous thrombosis, occurs when a vein (blood clot) forms deep in the veins of the body due to vein damage or slow blood flow. Blood clots can completely or partially stop the flow of blood through a vein. DVTs are usually found in the leg, thigh or pelvis, but can also occur in the arm, brain, bowel, liver or kidney.

• According to the World Health Organization (WHO), cardiovascular diseases account for nearly 17.9 million deaths annually, representing 32% of all global deaths. This growing burden has driven the increased use of anticoagulant medications like enoxaparin sodium for deep vein thrombosis and pulmonary embolism prevention. In 2024, over 40% of hospitalized cardiovascular patients globally were prescribed low molecular weight heparins, indicating a significant rise in clinical utilization.

• As per the U.S. Food and Drug Administration (FDA), more than 12 generic enoxaparin formulations have received approval in the past five years, promoting accessibility in both developed and emerging markets. The FDA notes that generics have reduced treatment costs by nearly 35%, improving patient adherence and increasing hospital procurement volumes across North America and Europe.

Download Free Sample to learn more about this report

ENOXAPARIN SODIUM MARKET SEGMENTATION

By Type

According to type, the market can be segmented into 30 mg/0.3mL, 60 mg/0.6mL, 100 mg/1mL, 120 mg/0.8mL, 150 mg/1mL. 30 mg/0.3mL is anticipated to be the leading segment.

By Application

Based on application, the market can be divided into Hospital, Clinic, Others. Hospital will be dominating segment.

DRIVING FACTORS

Increase in chronic cardiovascular and other diseases fuel the market growth

The incidence of cardiovascular diseases is increasing in important age groups such as the elderly population, which is expected to increase the demand for this product, which is one of the major market drivers. Almost all diseases like atrial fibrillation, heart attack and stroke remain prevalent during the forecast period. In 2020, majority of Americans died from cardiovascular disease, according to the Centers for Disease Control and Prevention. There are only a few factors that influence the significant potential and current patient population represented by these trends and statistics, resulting in high demand for these products. The market is also fueled by the fact that people are increasingly aware of the effectiveness of drugs in the treatment of various heart diseases. This in turn paves the way for market growth.

Increasing number of drugs approved by Food and Drug Administration fuel the market growth

Increasing number of drugs approved by Food and Drug Administration and increasing elderly population are some of the factors driving the growth of the market. Increasing awareness about the treatment of various cardiovascular diseases is driving the growth of the market. In addition, the growth of the enoxaparin sodium market is fueled by rising healthcare costs, increasing research and development activities of many pharmaceutical companies, launching of newly developed drugs.

• According to the Centers for Disease Control and Prevention (CDC), an estimated 900,000 Americans are affected by venous thromboembolism (VTE) each year, leading to approximately 100,000 deaths. This has prompted large-scale governmental healthcare initiatives encouraging the use of enoxaparin sodium for prophylaxis. The CDC’s hospital safety programs have improved compliance rates with anticoagulant protocols by 28% since 2020.

• Based on data from the United Nations Department of Economic and Social Affairs (UNDESA), the global population aged 65 years and above reached 771 million in 2023, a 19% increase over the past decade. With higher rates of orthopedic and cardiac surgeries — averaging 310 procedures per 100,000 people worldwide — the medical need for anticoagulant therapy has surged, positively influencing enoxaparin demand.

RESTRAINING FACTORS

Adverse effects of enoxaparin may hinder the market growth

The major factors restraining the growth of the global enoxaparin sodium market are adverse effects of enoxaparin sodium. The adverse reaction of enoxaparin-induced thrombocytopenia due to the use of enoxaparin is restraining the enoxaparin sodium market growth. In addition, adults receiving enoxaparin sodium for medical or general surgical indications are at greater risk of HIT than children or obstetric patients.

• According to the European Medicines Agency (EMA), about 6% of enoxaparin sodium users experience moderate to severe bleeding complications during therapy. This safety concern limits its long-term use, especially among elderly and high-risk patients. Hospitals have consequently increased clinical monitoring costs by 15–20%, adding to the total treatment burden.

• As reported by the National Institutes of Health (NIH), the use of direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban has increased by 42% in the past five years. These alternatives, requiring less monitoring and offering simplified dosing, are gradually replacing injectable low molecular weight heparins like enoxaparin sodium in certain treatment settings.

• Download Free Sample to learn more about this report

•  

ENOXAPARIN SODIUM MARKET REGIONAL INSIGHTS

North America is expected to dominate the market due to rising patient awareness

North America is expected to dominate the market due to factors such as increasing disease burden, increasing geriatric population, and increasing product approvals. North America dominated the market and accounted for the largest enoxaparin sodium market share of revenue in 2022. This is due to the increase in cardiovascular diseases and injuries. Moreover, rising healthcare costs and rising patient awareness in the region are factors contributing to the high share of the region. According to the CDC, in 2022, the majority of people in the U.S. will die from heart disease each year, accounting for one in four deaths, and it was one of the leading causes of death in the country.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios. Key industry players in the antacid tablet market have a significant impact on market dynamics. These companies are at the forefront of research and development, consistently introducing innovative formulations and product variations. Their focus on convenience and effectiveness sets industry standards and influences market growth.

• Cardinal Health: According to the U.S. Department of Health and Human Services (HHS), Cardinal Health supplies pharmaceutical products, including enoxaparin sodium, to over 29,000 hospitals and healthcare centers across the United States. Their distribution network supports approximately 1.2 billion doses of injectable pharmaceuticals annually, enhancing accessibility to critical anticoagulant therapies.

• Shenzhen Techdow Pharmaceutical: According to the China National Medical Products Administration (NMPA), Shenzhen Techdow Pharmaceutical is one of the largest exporters of enoxaparin sodium in Asia, supplying to more than 80 countries. The company’s annual production capacity exceeded 200 metric tons in 2024, representing over 25% of China’s total low molecular weight heparin output.

List of Top Enoxaparin Sodium Companies

• Cardinal Health (U.S.)
• Shenzhen Techdow Pharmaceutical (China)
• Teva Parenteral Medicines (Israel)
• Actavis Pharma Company (U.S.)
• Jianyou
• Sanodz (Switzerland)
• Sanofi (France)
• Amphastar Pharmaceuticals, Inc. (U.S.)
• NorthStar Rx (U.S.)
• Winthrop U.S. (U.S.)

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.